.png){kind=icon}
.png){kind=icon}
Return
NF-κB decoy polyplexes decrease P-glycoprotein-mediated multidrug resistance in colorectal cancer cells
.png){kind=icon}
OA
AI
DOI：10.1038/cgt.2016.17.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Multidrug resistance (MDR), a major cause for chemotherapy failure, has been linked to upregulation of ATP-dependent membrane efflux systems that limit intracellular. accumulation, of cytotoxic anticancer agents. P-glycoprotein (P-gp) encoded by the human ABCB1 gene was the first efflux transporter identified to contribute to MDR. ABCB1 gene expression is correlated with constitutive activation of the NF-kappa B signaling pathway in tumor cells. The objective of this research is to modulate P-gp activity in colon cancer cells using NF-kappa B decoy oligodeoxynucleotides (ODNs) that are effectively delivered into the nucleus of colorectal cancer cells by self-assembling nonviral nanoparticles comprising the novel poly[N-(2-hydroxpropyl)methacrylamide]-poly(N,N-dimethylaminoethylmethacrylate) diblock copolymer (pHPMA-b-pDMAEMA). Ethidium bromide intercalation and gel retardation assays demonstrated high DNA condensation capacity of pHPMA-b-pDMAEMA. Nanoparticles prepared with and without decoy ODNs did not significantly compromise cellular safety at N/P ratios <= 4. Transfection efficiency of pHPMA-b-pDMAEMA polyplexes (N/P = 4) in Caco-2 cells was comparable to TurboFect transfection standard, resulting in a 98% reduction in P-gp protein levels. As a pharmacodynamic consequence, intracellular accumulation of the P-gp substrate Rhodamine123 significantly increased by almost twofold. In conclusion, NF-kappa B ODN polyplexes fabricated with pHPMA-b-pDMAEMA polymer effectively reduced P-gp-mediated efflux activity in Caco-2 cells, suggesting successful interference with NF-kappa B-binding sites in the promoter region of the ABCB1 gene.
Keywords:
GENE DELIVERY
IN-VIVO
COMPLEXES
POLYMER
POLYETHYLENIMINE
TRANSFECTION
ACTIVATION
EXPRESSION
OLIGONUCLEOTIDES
PHARMACOKINETICS
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
5
Papers:
2.9K
Citations:
5.3K
Organization
View more organizations